CJC-1295

Description

Pharmacokinetics

CJC-1295 works especially well by the elongation of its half-life. GHRH, while achieving the same effects and results without CJC-1295, is readily discarded through the action of dipeptidyl amino peptidase IV, also known as DPP-IV.[2] In essence, regular action of GHRH is subdued by a negative feedback loop process, leading to a short half-life of roughly 7 minutes, and limited plasma and insulin production. CJC-1295 quells DPP-IV, and therefore seems to lead to heightened activity. 

Scientific Studies 

In one study, performed on individuals ranging from 21 to 61 years old, CJC-1295 was observed in action. Through subcutaneous injection, both weekly and biweekly, the presence of CJC-1295 pointed towards higher levels of plasma and insulin within the subjects’ blood. This was observed at dosages of 30 to 60 micrograms per kilogram of body weight.[1]

Sources:

[1] https://www.ncbi.nlm.nih.gov/pubmed/16352683

[2] http://neobiolab.com/research/current-research-findings-regarding-cjc-1295

[3] https://absoluterx.com/cjc-1295/

Additional information